Succinylacetoacetate (BioDeep_00000169723)
human metabolite
代谢物信息卡片
化学式: C8H10O6 (202.0477)
中文名称:
谱图信息:
最多检出来源 Mus musculus(not specific) 1.43%
分子结构信息
SMILES: C(CC(=O)O)C(=O)CC(=O)CC(=O)O
InChI: InChI=1S/C8H10O6/c9-5(1-2-7(11)12)3-6(10)4-8(13)14/h1-4H2,(H,11,12)(H,13,14)
描述信息
Succinylacetoacetate is an intermediate that arises due to the incomplete breakdown of tyrosine (PMID: 7171740). It is produced as a result of defects in the enzyme called fumarylacetoacetase. Fumarylacetoacetase normally catalyzes the hydrolysis of 4-fumarylacetoacetate into fumarate and acetoacetate. If present in sufficiently high levels, succinylacetoacetate can act as an acidogen, an oncometabolite, and a metabotoxin. An acidogen is an acidic compound that induces acidosis, which has multiple adverse effects on many organ systems. An oncometabolite is an endogenous metabolite that causes cancer. A metabotoxin is an endogenously produced metabolite that causes adverse health effects at chronically high levels. Chronically high levels of succinylacetoacetate are associated with tyrosinemia type I. Type I tyrosinemia is an inherited metabolic disorder due to a shortage of the enzyme fumarylacetoacetate hydrolase that is needed to break down tyrosine. Patients usually develop features such as hepatic necrosis, renal tubular injury, and hypertrophic cardiomyopathy. Neurologic and dermatologic manifestations are also possible as well as hepatocellular carcinoma. The urine of tyrosinemia patients has an odour of cabbage or rancid butter. Succinylacetoacetate is an organic acid. Abnormally high levels of organic acids in the blood (organic acidemia), urine (organic aciduria), the brain, and other tissues lead to general metabolic acidosis. Acidosis typically occurs when arterial pH falls below 7.35. In infants with acidosis, the initial symptoms include poor feeding, vomiting, loss of appetite, weak muscle tone (hypotonia), and lack of energy (lethargy). These can progress to heart, liver, and kidney abnormalities, seizures, coma, and possibly death. These are also the characteristic symptoms of untreated tyrosinemia. Many affected children with organic acidemias experience intellectual disability or delayed development. Succinylacetoacetate appears to function as an oncometabolite (similar in function to succinate, another oncometabolite) as patients with high levels of this compound often develop hepatocellular carcinoma (PMID: 20003495).
同义名列表
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:87999
- PubChem: 125181
- HMDB: HMDB0240258
- chemspider: 111425
- CAS: 65115-74-4
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
1 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:
- PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。
亚细胞结构定位 | 关联基因列表 |
---|
文献列表
- David Cassiman, Renate Zeevaert, Elisabeth Holme, Eli-Anne Kvittingen, Jaak Jaeken. A novel mutation causing mild, atypical fumarylacetoacetase deficiency (Tyrosinemia type I): a case report.
Orphanet journal of rare diseases.
2009 Dec; 4(?):28. doi:
10.1186/1750-1172-4-28
. [PMID: 20003495] - S Lindstedt, E Holme, E A Lock, O Hjalmarson, B Strandvik. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.
Lancet (London, England).
1992 Oct; 340(8823):813-7. doi:
10.1016/0140-6736(92)92685-9
. [PMID: 1383656] - H Schierbeek, R Berger. Determination of succinylacetone and succinylacetoacetate in physiological samples as the common product 5(3)-methyl-3(5)-isoxazole propionic acid using an isotope dilution method and mass spectrometry.
Clinica chimica acta; international journal of clinical chemistry.
1989 Oct; 184(3):243-50. doi:
10.1016/0009-8981(89)90057-0
. [PMID: 2611997] - M Tuchman, D K Freese, H L Sharp, M L Ramnaraine, N Ascher, J R Bloomer. Contribution of extrahepatic tissues to biochemical abnormalities in hereditary tyrosinemia type I: study of three patients after liver transplantation.
The Journal of pediatrics.
1987 Mar; 110(3):399-403. doi:
10.1016/s0022-3476(87)80501-2
. [PMID: 3546650] - S K Wadman, M Duran, D Ketting, L Bruinvis, F J van Sprang, R Berger, G P Smit, B Steinmann, J V Leonard, P Divry, J P Farriaux, B Cartigny. Urinary excretion of deuterated metabolites in patients with tyrosinemia type I after oral loading with deuterated L-tyrosine.
Clinica chimica acta; international journal of clinical chemistry.
1983 May; 130(2):231-8. doi:
10.1016/0009-8981(83)90120-1
. [PMID: 6872257] - B Lindblad, G Steen. Identification of 4,6-dioxoheptanoic acid (succinylacetone), 3,5-dioxooctanedioic acid (succinylacetoacetate) and 4-Oxo-6-hydroxyheptanoic acid in the urine from patients with hereditary tyrosinemia.
Biomedical mass spectrometry.
1982 Oct; 9(10):419-24. doi:
10.1002/bms.1200091003
. [PMID: 7171740] - S P Fällström, B Lindblad, G Steen. On the renal tubular damage in hereditary tyrosinemia and on the formation of succinylacetoacetate and succinylacetone.
Acta paediatrica Scandinavica.
1981; 70(3):315-20. doi:
10.1111/j.1651-2227.1981.tb16558.x
. [PMID: 7246125]